| Final Results of the GRECCAR-6 Trial on Waiting Period Following Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer: 5 Years of Follow-up.Dis Colon Rectum疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39508462无 PMCID | 2025-Feb-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.JAMA Dermatol | PMID 39602139PMC11840645 | 2025-Feb-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma.Rhinology | PMID 39660637无 PMCID | 2025-Feb-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy.JAMA Ophthalmol | PMID 39699886PMC11843360 | 2025-Feb-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial.JAMA Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39699905PMC11843352 | 2025-Feb-01 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 无 KM 图 |
| Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine.Obstet Gynecol | PMID 39746206PMC11731028 | 2025-Feb-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial.Obstet Gynecol | PMID 39746212PMC11731064 | 2025-Feb-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39874977无 PMCID | 2025-Feb-01 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 无 KM 图 |
| Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.Lancet | PMID 39892911无 PMCID | 2025-Feb-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses.J Drugs Dermatol | PMID 39913230无 PMCID | 2025-Feb-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety, pharmacokinetics and pharmacodynamics of multiple-dose noiiglutide (SHR20004), a novel GLP-1 receptor agonist, in Chinese obese subjects without diabetes mellitus.Diabetes Obes Metab | PMID 39618170无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics.Emerg Infect Dis | PMID 39983682PMC11845141 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The efficacy and safety of a quadrivalent live attenuated influenza nasal vaccine in Japanese children: A phase 3, randomized, placebo-controlled study.J Infect Chemother | PMID 38959995无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.J Hepatol | PMID 39089633无 PMCID | 2025-Feb | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Disease Activity and Therapeutic Response to Pegcetacoplan for Geographic Atrophy Identified by Deep Learning-Based Analysis of OCT.Ophthalmology | PMID 39151755无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.Ophthalmology | PMID 39182627无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association Between Baseline Macular Morphologic Features on Optical Coherence Tomography and Visual Outcomes in Patients with Vogt-Koyanagi-Harada Disease.Ocul Immunol Inflamm | PMID 39190826PMC11785501 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD.Chest | PMID 39197510无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS).Am J Respir Crit Care Med | PMID 39213002无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of macitentan in Fontan-palliated patients: 52-week randomized, placebo-controlled RUBATO Phase 3 trial and open-label extension.J Thorac Cardiovasc Surg | PMID 39216715无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes.ESC Heart Fail | PMID 39226189PMC11769639 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial.Eur Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39261236无 PMCID | 2025-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo-Controlled, Phase 3 Study.Arthritis Rheumatol | PMID 39300513PMC11782106 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase 3 Study.Arthritis Rheumatol | PMID 39300596PMC11782105 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Kansas City Cardiomyopathy Questionnaire in Relation to New York Heart Association Class.J Card Fail | PMID 39349158PMC11975531 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Colchicine effect on biomarkers of cardiac remodelling and atherosclerosis in ST-elevation myocardial infarction: A randomized controlled trial.Br J Clin Pharmacol | PMID 39359014无 PMCID | 2025-Feb | 0.90 | The study is a Phase III randomized controlled trial evaluating colchicine in STEMI patients, but it is not an oncology study and does not report a time-to-event efficacy endpoint. The primary outcomes are biomarkers (sST2, interleukin-1β, lipid profiles) and cardiac function (left ventricular ejection fraction). | 待处理 |
| INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39365958无 PMCID | 2025-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial.J Clin Oncol | PMID 39374473无 PMCID | 2025-Feb | 0.75 | Metadata establishes all primary eligibility criteria: oncology (NSCLC), human, randomized (multicenter RCT), phase III (explicitly stated), time-to-event primary endpoint (PFS) and secondary endpoint (OS) with HRs. The intervention includes a drug (EGFR-TKI). The report is the original results of a definitive trial. The deterministic review flagged 'drug_intervention_unclear', but the abstract explicitly describes EGFR-TKIs as the standard-of-care comparator in both arms, making it a drug-containing intervention. | 待处理 |
| Comparative Analysis of Electrosurgical Energy and Hemostatic Sealant for Hemostasis in Laparoscopic Ovarian Cystectomy: A Randomized Controlled Phase III Study.J Minim Invasive Gynecol | PMID 39374647无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).J Clin Oncol已检查 2 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图。 | PMID 39383487PMC11776878 | 2025-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.Lancet Infect Dis | PMID 39389071无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial.J Thorac Oncol | PMID 39395662无 PMCID | 2025-Feb | 0.95 | This is a secondary subgroup analysis of a Phase III surgical oncology trial. It does not meet the inclusion criteria because it lacks a drug-containing intervention and is not the primary report of the trial's efficacy results. | 待处理 |
| Drug-Drug Interaction Between Dihydroartemisinin-Piperaquine and Sulfadoxine-Pyrimethamine During Malaria Chemoprevention in Pregnant Women.Clin Pharmacol Ther | PMID 39402742PMC11747899 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial.J Am Acad Dermatol | PMID 39423930无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Misoprostol as Oral Solution or Oral Tablet for Induction of Labour (MISOBEST): A Randomised Controlled Non-Inferiority Trial.BJOG | PMID 39440409PMC11704078 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39442617无 PMCID | 2025-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Improvement of platysma prominence with onabotulinumtoxinA: Safety and efficacy results from a randomized, double-blinded, placebo-controlled phase 3 trial.J Am Acad Dermatol | PMID 39442886无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2.J Am Acad Dermatol | PMID 39447758无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Real-World Evidence of Crizanlizumab Showing Reductions in Vaso-Occlusive Crises and Opioid Usage in Sickle Cell Disease.Eur J Haematol | PMID 39473076PMC11707818 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Low-dose and ultra-low-dose estradiol and dydrogesterone in postmenopause: an analysis by body mass index.Climacteric | PMID 39475406无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39477187无 PMCID | 2025-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.Lancet Respir Med | PMID 39486424无 PMCID | 2025-Feb | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Efficacy and safety of ZX-7101A, an inhibitor of influenza cap-dependent endonuclease, in adults with uncomplicated influenza: a randomized, double-blind, placebo-controlled phase 2/3 trial.Clin Microbiol Infect | PMID 39490410无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study.Diabetes Obes Metab | PMID 39497468PMC11701187 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham.CPT Pharmacometrics Syst Pharmacol | PMID 39497616PMC11812941 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39521434无 PMCID | 2025-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial.Ann Oncol | PMID 39532203无 PMCID | 2025-Feb | 0.45 | The trial is a Phase III randomized trial in human oncology with a drug intervention (capecitabine), but the primary efficacy endpoint is organ preservation rate (a binary outcome), not a standard time-to-event endpoint (OS, PFS, DFS, etc.). While local regrowth is a time-to-event outcome, it is not presented as a primary or key secondary endpoint with Kaplan-Meier analysis or hazard ratios in the abstract. Therefore, it does not meet the criteria for inclusion in a Kaplan-Meier digitization cohort focused on time-to-event efficacy endpoints. | 待处理 |
| Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies.Eur J Haematol | PMID 39535306PMC11707819 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Psychometric evaluation of the Functional Assessment of chronic illness therapy-fatigue (FACIT-Fatigue) in adults with moderately to severely active Crohn's disease.Qual Life Res | PMID 39537976PMC11865103 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension.Br J Haematol | PMID 39552477PMC11829145 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |